Application of oncolytic virus in tumor therapy

J Med Virol. 2023 Apr;95(4):e28729. doi: 10.1002/jmv.28729.

Abstract

Oncolytic viruses (OVs) can selectively kill tumor cells without affecting normal cells, as well as activate the innate and adaptive immune systems in patients. Thus, they have been considered as a promising measure for safe and effective cancer treatment. Recently, a few genetically engineered OVs have been developed to further improve the effect of tumor elimination by expressing specific immune regulatory factors and thus enhance the body's antitumor immunity. In addition, the combined therapies of OVs and other immunotherapies have been applied in clinical. Although there are many studies on this hot topic, a comprehensive review is missing on illustrating the mechanisms of tumor clearance by OVs and how to modify engineered OVs to further enhance their antitumor effects. In this study, we provided a review on the mechanisms of immune regulatory factors in OVs. In addition, we reviewed the combined therapies of OVs with other therapies including radiotherapy and CAR-T or TCR-T cell therapy. The review is useful in further generalize the usage of OV in cancer treatment.

Keywords: combined therapy; genetic engineering; immunotherapy; oncolytic virus; tumor treatment.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Immunologic Factors
  • Immunotherapy
  • Neoplasms* / therapy
  • Oncolytic Virotherapy*
  • Oncolytic Viruses* / genetics

Substances

  • Immunologic Factors